Pretreatment CA19‐9 Predicts Survival in Pancreatic Cancer With Optimal Response to Neoadjuvant Therapy
In this select cohort of PDAC patients with optimal NAT response, pre-NAT CA19-9 ≥ 400U/mL is strongly associated with decreased DFS and OS.
Authors
- Asmita Chopra (ORCID: https://orcid.org/0000-0002-5908-3993)
- Carl Schmidt (ORCID: https://orcid.org/0000-0001-8863-7409)
- Brian A. Boone (ORCID: https://orcid.org/0000-0001-9006-059X)
- Sebastiaan Ceuppens (ORCID: https://orcid.org/0000-0003-4978-8647)
- Patricio Marcelo Polanco (ORCID: https://orcid.org/0000-0002-1719-1208)
- Emile Farah
- Anthony Gebran (ORCID: https://orcid.org/0000-0003-3311-9908)
- Mark S. Talamonti (ORCID: https://orcid.org/0000-0001-7561-6916)
- Robin Schmitz (ORCID: https://orcid.org/0000-0003-1286-0457)
- Sarah B. Hays (ORCID: https://orcid.org/0000-0002-1587-3897)
- Melissa Ellen Hogg (ORCID: https://orcid.org/0000-0001-5641-4438)
- Alessandro Paniccia
- Kristen Ranson
- Herbert J. Zeh
- Hao Liu
- Aram Rojas
- Amer H. Zureikat
- Nikhil V. Tirukkovalur
- Kenneth K. Lee
Institutions
- West Virginia University (US)
- NorthShore University HealthSystem (US)
- Erasmus MC (NL)
- University of Pittsburgh Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- Journal of Surgical Oncology
- Published
- 2025-12-31
- DOI
- https://doi.org/10.1002/jso.70179
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00